Mallinckrodt (MNK) Tops Q3 EPS by 23c

Mallinckrodt (NYSE: MNK) reported Q3 EPS of $2.05, $0.23 better than the analyst estimate of $1.82. Revenue for the quarter came in at $965.1 million versus the consensus estimate of $985.3 million.

"Mallinckrodt reported another solid quarter, with meaningful top- and bottom-line growth in our Specialty Brands segment. The revenue contributed by specialty biopharmaceutical products continues to increase as an overall percentage of net sales," said Mark Trudeau, Chief Executive Officer and President of Mallinckrodt. "The recent announcement of the planned divestiture of our contrast media and delivery systems business further demonstrates our commitment to the strategy we have outlined, as we refine our portfolio to further transform the company into a leading specialty biopharmaceutical company focused on long-term, durable and sustained growth."

For earnings history and earnings-related data on Mallinckrodt (MNK) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Palogic urges Granite Point Mortgage to cut costs, halt new loans
• Benchmark Reiterates Speculative Buy Rating on Nephros (NEPH) Following Strong Q2 Results